The $2,000 Part D Out-of-Pocket Cap: What It Means for You

Starting in 2025 and continuing into 2026, Medicare Part D enrollees now have a hard annual out-of-pocket cap of $2,000 on covered prescription drugs — one of the most significant Medicare improvements in decades.

What Changed

Before the Inflation Reduction Act (IRA), Part D had no true out-of-pocket cap. Beneficiaries in the "catastrophic" phase still paid 5% of drug costs with no ceiling. For someone on expensive specialty medications, annual drug costs could reach $10,000 or more.

The IRA capped this at $2,000 per year starting in 2025, phased down from the prior $7,400 threshold.

Who Benefits Most

The $2,000 cap is most impactful for people taking: - High-cost cancer medications - Specialty biologics (MS drugs, rheumatoid arthritis treatments) - Expensive brand-name diabetes or cardiovascular drugs

If your annual drug costs would have exceeded $2,000 in prior years, you now hit the cap and pay $0 for the rest of the year.

The Medicare Prescription Payment Plan

Also introduced by the IRA: beneficiaries can now spread their drug costs across the year in equal monthly payments rather than paying large amounts upfront. This is called the Medicare Prescription Payment Plan (M3P) and is available through your Part D plan.

Does This Change Which Part D Plan Is Best?

Yes. With the $2,000 cap, the value calculation for Part D plans has shifted. For people on expensive medications, a plan with a higher premium but better drug coverage (lower copays before the cap) may now be more cost-effective. Compare plans based on your actual drug list using the Medicare Plan Finder at medicare.gov.

See our [Medicare Part D guide](/medicare-part-d) for more.